Folate-targeted nanoparticles based on albumin and albumin/alginate mixtures as controlled release systems of tamoxifen: Synthesis and in vitro characterization

Pharmaceutical Research

Volumn 31, Issue 1, 2014, Pages 182-193

  Martinez A ^a   Olmo, R ^b   Iglesias, I ^a   Teijon J M ^b   Blanco, M D ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

folic acid; nanoparticles; natural polymers; tamoxifen; targeted therapy

Indexed keywords

ALBUMIN; ALGINIC ACID; BOVINE SERUM ALBUMIN; FOLATE RECEPTOR; FOLIC ACID; NANOPARTICLE; TAMOXIFEN;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; DISULFIDE BOND; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

ALGINATES; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FOLIC ACID; GLUCURONIC ACID; HELA CELLS; HEXURONIC ACIDS; HUMANS; MCF-7 CELLS; NANOPARTICLES; PARTICLE SIZE; SERUM ALBUMIN, BOVINE; TAMOXIFEN;

EID: 84891624041     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1151-z     Document Type: Article

References (42)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13(8):790-801.
2. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311-30. (Pubitemid 40316520)
3. Park JH, von Maltzahn G, Xu MJ, Fogal V, Kotamraju VR, Ruoslahti E, et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A. 2010;107(3):981-6.
4. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.
5. Ranganathan R, Madanmohan S, Kesavan A, Baskar G, Krishnamoorthy YR, Santosham R, et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomed. 2012;7:1043-60.
6. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carr Syst. 2009;26(6):523-80.
7. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41(2):147-62. (Pubitemid 30122955)
8. Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem. 2010;53(19):6811-24.
9. Ulbrich K, Michaelis M, Rothweiler F, Knobloch T, Sithisarn P, Cinatl J, et al. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int J Pharm. 2011;406(1-2):128-34.
10. Yang SJ, Lin FH, Tsai HM, Lin CF, Chin HC, Wong JM, et al. Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. Biomaterials. 2011;32(8):2174-82.
11. Benichou A, Aserin A, Garti N. Protein-Polysaccharide Interactions for Stabilization of Food Emulsions. J Dispers Sci Technol. 2002;23(1-3):93-123. (Pubitemid 34781170)
12. Yi YM, Yang TY, Pan WM. Preparation and distribution of 5-fluorouracil (125)I sodium alginate-bovine serum albumin nanoparticles. World J Gastroenterol. 1999;5(1):57-60.
13. Ameller T, Legrand P, Marsaud V, Renoir JM. Drug delivery systems for oestrogenic hormones and antagonists: the need for selective targeting in estradiol-dependent cancers. J Steroid Biochem Mol Biol. 2004;92(1-2):1-18. (Pubitemid 39486058)
14. Martinez A, Benito-Miguel M, Iglesias I, Teijon JM, Blanco MD. Tamoxifen-loaded thiolated alginate-albumin nanoparticles as antitumoral drug delivery systems. J Biomed Mater Res A. 2012;100A(6):1467-76.
15. Martínez A, Iglesias I, Lozano R, Teijón JM, Blanco MD. Synthesis and characterization of thiolated alginate-albumin nanoparticles stabilized by disulfide bonds. Evaluation as drug delivery systems. Carbohydr Polym. 2011;83(3):1311-21.
16. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev. 2005;57(11):1569-82. (Pubitemid 41443470)
17. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269(5):3198-204. (Pubitemid 24237629)
18. Zhang L, Hou S, Mao S, Wei D, Song X, Lu Y. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm. 2004;287(1-2):155-62. (Pubitemid 39487253)
19. Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Anal Technol Biomed Life Sci. 2003;791(1-2):245-53. (Pubitemid 36638757)
20. MacCallum J, Cummings J, Dixon JM, Miller WR. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma. J Chromatogr B Biomed Appl. 1996;678(2):317-23. (Pubitemid 26168040)
21. Hu FX, Neoh KG, Kang ET. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials. 2006;27(33):5725-33. (Pubitemid 44294822)
22. Chawla JS, Amiji MM. Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm. 2002;249(1-2):127-38. (Pubitemid 35333439)
23. Beerli RR, Dreier B, Barbas 3rd CF. Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci U S A. 2000;97(4):1495-500. (Pubitemid 30118469)
24. Corona G, Giannini F, Fabris M, Toffoli G, Boiocchi M. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer. 1998;75(1):125-33. (Pubitemid 28113987)
25. Shi G, Guo W, Stephenson SM, Lee RJ. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. J Control Release. 2002;80(1-3):309-19. (Pubitemid 34273768)
26. Han X, Liu J, Liu M, Xie C, Zhan C, Gu B, et al. 9-NC-loaded folate-conjugated polymer micelles as tumor targeted drug delivery system: preparation and evaluation in vitro. Int J Pharm. 2009;372(1-2):125-31.
27. Martinez A, Muniz E, Iglesias I, Teijon JM, Blanco MD. Enhanced preclinical efficacy of tamoxifen developed as alginate-cysteine/disulfide bond reduced albumin nanoparticles. Int J Pharm. 2012;436(1-2):574-81.
28. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3-19. (Pubitemid 32209229)
29. Arnedo A, Espuelas S, Irache JM. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm. 2002;244(1-2):59-72. (Pubitemid 35245446)
30. Aynie I, Vauthier C, Chacun H, Fattal E, Couvreur P. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1999;9(3):301-12. (Pubitemid 29361064)
31. Abbasalipurkabir R, Salehzadeh A, Abdullah R. Delivering Tamoxifen within Solid Lipid Nanoparticles. Pharm Technol. 2011;35(4):74-9.
32. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003;42(4):361-72. (Pubitemid 36433876)
33. Martinez A, Arana P, Fernández A, Olmo R, Teijón C, Blanco MD. Synthesis and characterisation of alginate/chitosan nanoparticles as tamoxifen controlled delivery systems. Journal of Microencapsulation.
34. Geszke M, Murias M, Balan L, Medjahdi G, Korczynski J, Moritz M, et al. Folic acid-conjugated core/shell ZnS:Mn/ZnS quantum dots as targeted probes for two photon fluorescence imaging of cancer cells. Acta Biomater. 2011;7(3):1327-38.
35. Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A. 1985;82(23):7889-93. (Pubitemid 16179869)
36. Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, et al. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem. 2005;16(5):1181-8. (Pubitemid 41368119)
37. Suzuki T, Hisakawa S, Itoh Y, Suzuki N, Takahashi K, Kawahata M, et al. Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007;17(15):4208-12. (Pubitemid 47028601)
38. Wilhelm C, Gazeau F, Roger J, Pons JN, Bacri JC. Interaction of Anionic Superparamagnetic Nanoparticles with Cells: Kinetic Analyses of Membrane Adsorption and Subsequent Internalization. Langmuir. 2002;18(21):8148-55. (Pubitemid 35383114)
39. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials. 2003;24(6):1001-11. (Pubitemid 36024170)
40. Jansen G. Receptor-, and carrier-mediated transport systems for folates, and antifolates. In: Jackman AL, editor. Antifolate drugs in cancer therapy. Totowa: Humana Press; 1999. p. 293-321.
41. Ke CY, Mathias CJ, Green MA. The folate receptor as a molecular target for tumor-selective radionuclide delivery. Nucl Med Biol. 2003;30(8):811-7. (Pubitemid 38040989)
42. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A. 1991;88(13):5572-6. (Pubitemid 21914787)